58 related articles for article (PubMed ID: 37243913)
1. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Masarova L; Bose P; Pemmaraju N; Zhou L; Pierce S; Estrov Z; Kantarjian H; Verstovsek S
Acta Haematol; 2023; 146(6):522-529. PubMed ID: 37699357
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti F; Lou Y; Chevli M; Abraham P
Future Oncol; 2023 Nov; ():. PubMed ID: 37991002
[TBL] [Abstract][Full Text] [Related]
3. Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.
Chiu CY; John TM; Matsuo T; Wurster S; Hicklen RS; Khattak RR; Ariza-Heredia EJ; Bose P; Kontoyiannis DP
J Fungi (Basel); 2024 Mar; 10(4):. PubMed ID: 38667935
[TBL] [Abstract][Full Text] [Related]
4. Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D; Arcasoy MO; Henrie R; Cerquozzi S; Kamble R; Al-Hadidi S; Yacoub A; Singh AK; Elsawy M; Sirhan S; Smith E; Marcoux C; Viswabandya A; Daly A; Sibai H; McNamara C; Shi Y; Xu W; Lajkosz K; Foltz L; Gupta V
Bone Marrow Transplant; 2024 Feb; 59(2):295. PubMed ID: 38279008
[No Abstract] [Full Text] [Related]
5. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib.
Stoeva V; Petrova G; Mitov K; Tachkov K
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513888
[TBL] [Abstract][Full Text] [Related]
6. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Chifotides HT; Verstovsek S; Bose P
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444441
[TBL] [Abstract][Full Text] [Related]
7. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
8. The role of therapy in the outcome of patients with myelofibrosis.
Masarova L; Bose P; Pemmaraju N; Daver NG; Sasaki K; Chifotides HT; Zhou L; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2023 Sep; 129(18):2828-2835. PubMed ID: 37243913
[TBL] [Abstract][Full Text] [Related]
9. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
10. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Moyo TK; Kishtagari A; Villaume MT; McMahon B; Mohan SR; Stopczynski T; Chen SC; Fan R; Huo Y; Moon H; Tang Y; Bejan CA; Childress M; Anderson I; Rawling K; Simons RM; Moncrief A; Caza R; Dugger L; Collins A; Dudley CV; Ferrell PB; Byrne M; Strickland SA; Ayers GD; Landman BA; Mason EF; Mesa RA; Palmer JM; Michaelis LC; Savona MR
Clin Cancer Res; 2023 Jul; 29(13):2375-2384. PubMed ID: 37036505
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy.
Benevolo G; Elli EM; Guglielmelli P; Ricco A; Maffioli M
Leuk Lymphoma; 2020 Jul; 61(7):1535-1547. PubMed ID: 32093511
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
13. Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Masarova L; Bose P; Pemmaraju N; Daver NG; Sasaki K; Chifotides HT; Zhou L; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2022 Apr; 128(8):1658-1665. PubMed ID: 35077575
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
